Literature DB >> 31931591

HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report.

Arturo Ciccullo1, Gianmaria Baldin1,2, Francesca Lombardi1, Alberto Borghetti3, Simona Di Giambenedetto1,3.   

Abstract

Entities:  

Year:  2020        PMID： 31931591     DOI： 10.1089/AID.2019.0270

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  1 in total

Review 1.  Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era.

Authors:  Valeria Cento; Carlo Federico Perno
Journal:  Diagnostics (Basel)       Date:  2021-04-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.